TechnologyNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 2104204ALMR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ALMR Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Alamar Biosciences, Inc. (ALMR), a Technology sector company. ALMR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Alamar Biosciences, Inc. reports quarterly revenue of $29.4M, net income of $-13.2M, an operating margin of -46.0%. ALMR trades on the Nasdaq exchange and files with the SEC under CIK 2104204. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alamar Biosciences, Inc. directly from SEC EDGAR.

Fun facts about Alamar Biosciences, Inc.

Quirks, history, and lore behind ALMR — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A small-cap U.S. life-science technology company listed on Nasdaq and headquartered in Southern California.
  • 2
    The Numbers
    A pre-profitability commercial-stage biotech tools firm with annual revenue in the tens of millions — still burning cash as it scales its platform.
  • 3
    The History
    Founded in the 2010s, it went public relatively recently and was built around the idea that standard protein and biomarker detection tools leave too much biology on the table.
  • 4
    The Secret
    Its core trick is squeezing hundreds of protein measurements out of a tiny blood sample simultaneously — crucial for cancer research, drug development, and diagnostics.
  • 5
    The Lore
    Its flagship platform is designed to democratize high-multiplex immunoassay testing, letting labs run panels that once required far more sample volume and far more money.
  • 6
    The Giveaway
    Its name evokes a navigator finding land, and its CLIA-certified lab and multiplex protein biomarker platform trade under the ticker ALMR on Nasdaq.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$29.4M

Net Income

Q2 2026

$-13.2M

Free Cash Flow

Q2 2026

$-15.0M

Operating Margin

Q2 2026

-46.0%

ROIC

Q2 2026

-17.3%

Get alerted when ALMR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alamar Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put ALMR on your watchlist

Track score changes the day Alamar Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ALMR a good stock to buy?

13F Pro's AI-powered analysis of Alamar Biosciences, Inc. (ALMR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALMR are available on the ALMR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALMR is classified as a small company.

Which hedge funds own ALMR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALMR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alamar Biosciences, Inc.'s investment landscape.